A growing body of evidence suggests that breast cancer recurrence risk is linked to lifestyle behaviors. This study examined correlations between breast cancer recurrence, risk reduction beliefs, and related behaviors among African American breast cancer survivors (AA BCSs). Study participants included 191 AA BCSs, mean age = 56.3 years, who completed a lifestyle assessment tool. Most respondents believed that being overweight (52.7%), lack of physical activity (48.7%), and a high fat diet (63.2%) are associated with breast cancer recurrence. Over 65% considered themselves overweight; one third (33.5%) agreed that losing weight could prevent recurrence, 33.0% disagreed, while the remaining 33.5% did not know; and nearly half (47.9%) believed that recurrence could be prevented by increasing physical activity. Almost 90% survivors with BMI < 25 Kg/M2 reported no recurrence compared to 75.7% with BMI ≥ 25 Kg/M2 (p = 0.06); nearly all of the women (99.2%) answered
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative metaanalyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995. Methods Information was available on 42 000 women in 78 randomised treatment comparisons (radiotherapy vs no radiotherapy, 23 500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment comparison were identified. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% (?10%, 17 000 women; ?10%, 25 000 women). Findings About three-quarters of the eventual local recurrence risk occurred during the first 5 years. In the comparisons that involved little (?10%) difference in 5-year local recurrence
Purpose: To investigate clinicopathological features in patients with recurrent colorectal cancer within 1 year and more than 1 year after curative resection. Materials and Methods: We retrospectively evaluated 103 patients with disease recurrence before versus after 1 year of resection. Thirty-two patients (31%) were diagnosed with recurrence less than 1 year after curative resection for colorectal cancer (early recurrence) and 71 (69%) after more than 1 year (non-early recurrence). Results: The early recurrence group displayed a significantly lower overall survival rate for both colon cancer (p=0, 01) and rectal cancer (p|0.001). Inadequate lymph node dissection was a significant predictor for early relapse. There were no statistically significant differences in clinicopathological variables such as age, sex, primary tumor localization, stage, depth of invasion, lymphovascular invasion and perineural invasion between the early and non-early recurrence groups. However, a K-ras mutation subgroup was
As a result, the number of breast cancer survivors is growing. Oncology Nursing Consultant, Adjunct Assistant Professor of Nursing As time passes, the risk of recurrence steadily decreases. A 2019 study in PLoS One reported that women with triple-negative breast cancer (an especially aggressive form of the disease) have a greater risk of recurrence and death if regional lymph nodes are involved.﻿﻿. American Cancer Society. The risk of recurrence is higher the more advanced their cancer was. Tamoxifen Can Reduce the Risk of Recurrence by 50 percent, What It Means to Have Stage 1 Non-Small Cell Lung Cancer, How Aromatase Inhibitors Prevent Breast Cancer Recurrence, Breast Cancer Recurrence in the Chest Wall After Mastectomy. What Is cancer recurrence? However, recurrence can happen even many years after treatment, which is why its important to be breast and body aware, and report any changes to your treatment team or GP. J Pain Symptom Manage. A 2016 study from MD Anderson reported that, ...
Objective. This study examined recurrence patterns in breast cancer patients younger than age of 40 and older than age of 75, two groups that are underrepresented in clinical trials and not routinely screened by mammography. Methods. The records of 230 breast cancer patients (n = 125 less than 40 and n = 105 greater than 75) who presented to the Emory University Department of Radiation Oncology for curative treatment between 1997 and 2010 were reviewed. Data recorded included disease presentation, treatment, and areas of locoregional recurrence. Results. Women less than 40 years of age had higher rates of locoregional recurrence (20% versus 7%, P = 0.004) and distant recurrence (18% versus 5%, P = 0.003) than patients above 75 years of age. On multivariate analysis, patient age less than 40 was the only significant predictor of locoregional recurrence (P = 0.018). In a univariate analysis of each age group, receptor status and postlumpectomy radiation were significant predictors of locoregional ...
While previous research has shown that consumption of alcohol is associated with an increased risk of breast cancer, there have been limited studies about alcohols role in patient prognosis and survival among those already diagnosed with breast cancer.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes Yehoda M Martei,1 Jennifer M Matro1,21Department of Medicine, Hematology-Oncology Division, 2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USAAbstract: Identifying patients at high risk of breast cancer recurrence has important implications not only for enabling the ability to provide accurate information to patients but also the potential to improve patient outcomes. Patients at high recurrence risk can be offered appropriate treatment to improve the overall survival. However, the major challenge is identifying patients with early-stage breast cancer at lower risk who may be spared potentially toxic therapy. The successful integration of molecular assays into clinical practice may address the problem of overtreatment and improve overall patient outcomes.Keywords: breast cancer, early stage, genomic assays, recurrence risk, recurrence score
Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.
WEDNESDAY, Sept. 11 (HealthDay News) -- Researchers say theyve identified a genetic indicator of the long-term risk of breast cancer recurrence.. They compared three gene signature methods of predicting the risk of recurrence in patients treated for estrogen-receptor (ER)-positive breast cancer. They found that only the breast cancer index (BCI) -- a biomarker based on the expression levels of seven tumor-specific genes -- accurately identifies patients who continues to be at risk for breast cancer recurrence after five years of treatment with either tamoxifen or anastrozole, a drug in the aromatase inhibitor class.. The other two methods examined in the study were the Oncotype Dx Recurrence Score, the current gold standard for guiding clinical decision making, and the ICH4 gene signature, which is used less frequently used.. All three methods were able to predict recurrence risk in the first five years, but only the breast cancer index was able to accurately assess long-term recurrence risk, ...
TY - JOUR. T1 - Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. AU - Aalders, Kim C.. AU - Postma, Emily L.. AU - Strobbe, Luc J.. AU - van der Heiden-van der Loo, Margriet. AU - Sonke, Gabe S.. AU - Boersma, Liesbeth J.. AU - van Diest, Paul J.. AU - Siesling, Sabine. AU - van Dalen, Thijs. PY - 2016. Y1 - 2016. N2 - Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.Patients and Methods: Women , 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were ...
TY - JOUR. T1 - The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. AU - Jobsen, Jan J.. AU - Van Der Palen, Job. AU - Ong, Francisca. AU - Meerwaldt, Jacobus H.. PY - 2003/11/1. Y1 - 2003/11/1. N2 - Purpose: To identify the importance of positive margins for invasive carcinoma on local control in patients treated with breast-conservative treatment (BCT). Methods and Materials: A total of 1752 BCT with known margins were analyzed. Fifty-five patients had a second BCT, leaving 1697 patients for analysis. The margins were positive in 193/1752 BCT (11%). The median follow-up was 78 months. Results: The 5- and 10-year local recurrence rates (LRR) were 3.1% and 6.9%, respectively, for negative margins vs. 5.6% and 12.2% for positive margins. A statistical interaction between age category and margin status was noted in relation to disease-free survival (DFS) and local relapse-free survival. The 5-year ...
Lets fight cancer together. New Hope Unlimited specializes in non-invasive, integrative Alternative Treatments for Recurrent Cancer. Call 480-666-1403 today.
The second type of recurrence is regional in nature. By regional we mean that the cancer has come back outside of the original breast and lymph node area. This is considered to be more serious than a local recurrence, but not as serious as a distant recurrence. The areas in which regional spread of the disease occur include the chest muscles (pectoral), the lymph nodes surrounding the neck area, the internal breast lymph nodes in the breast bone and rib areas and in the lymph nodes above the collarbone. This type of recurrence is rare. The third and most serious type of recurrence is called a distant recurrence. This is also referred to as a metastasis. The areas where distant spread can occur are most likely to occur are bone (25%), liver, brain, bone marrow, lungs or other organs. Sometimes this is referred to as metastatic disease or Stage IV breast cancer. The survival rate becomes much lower once metastasis occurs, with a life expectancy of 18 months on the average after discovering it. ...
To the best of our knowledge, the present study is the first to investigate the frequency and prognostic value of ALDH1 expression in IBTR tissues. The cut-off level for the classification of positive ALDH1 expression was set at ,1% in the current study, as there is no standardized cut-off level or method currently available. The ALDH1 positive cells were counted in hot spots, and positive ALDH1 expression was detected in 20% of the primary tumor samples and 23% of the IBTR tissue samples. The frequency of patients with ALDH1-expressing primary breast cancer (20%) in the current study was similar to that observed in previous studies (19, 17.5%) (10,11); however, the ALDH1 expression the in IBTR group (23%) was higher. It was hypothesized that this variation was due to the dissimilarities between the IBTR and primary tumors. IBTRs included new primary tumors and true recurrences following adjuvant therapy. Therefore, ALDH1-positive cancer stem cells within true recurrence were able to survive ...
There was no statistical difference in the 8 year local recurrence free survival in patients with VNPI scores of 3 or 4, regardless of whether or not radiation therapy was used (100% vs. 97%; P = not significant). Patients with VNPI scores of 5, 6, or 7 received a statistically significant 17% local recurrence free survival benefit when treated with radiation therapy (85% vs. 68%; P = 0.017). Patients with scores of 8 or 9, although showing the greatest relative benefit from radiation therapy, experienced local recurrence rates in excess of 60% at 8 years. Conclusions: ...
If there is a concern of a high-grade MCT, then other staging tests include abdominal ultrasonography, with ultrasound-guided aspirates of the liver and spleen, and bone marrow aspirates.. TREATMENT. The recommended treatment for MCTs is surgical excision. In dogs, lateral margins for excisionn should either be 2cm or equal to the maximal diameter of the MCT, whichever is greater, and one fascial layer for deep margins. In difficult locations where there is limited skin available for closure, preoperative biopsy is recommended as only 1 cm margins are required for excision of grade I MCTs and 2 cm margins for grade II MCTs. Local tumor recurrence rates using this approach ranges from 0% to 11%.. Radiation therapy has been recommended for locoregional tumor control in dogs with stage II MCT disease (i.e., dogs with lymph node metastasis) and possibly for the management of dogs with incompletely excised MCTs. Other options for the management of incompletely excised MCTs include monitoring ...
How the Breast Recurrence Score compares to traditional assessment methods, other genomic assays, the Breast DCIS Score, and to genetic tests.
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by Georgetown Lombardi Comprehensive Cancer Center.
Breast cancer recurrence can be overwhelming. Mental health strategies like cognitive behavioral therapy, support groups, mindfulness, and medications can help.
TY - JOUR. T1 - Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features. T2 - a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. AU - Rakovitch, E.. AU - Gray, R.. AU - Baehner, F. L.. AU - Sutradhar, R.. AU - Crager, M.. AU - Gu, S.. AU - Nofech-Mozes, S.. AU - Badve, S. S.. AU - Hanna, W.. AU - Hughes, L. L.. AU - Wood, W. C.. AU - Davidson, N. E.. AU - Paszat, L.. AU - Shak, S.. AU - Sparano, J. A.. AU - Solin, L. J.. PY - 2018/6/1. Y1 - 2018/6/1. N2 - Purpose: Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR after treatment by BCS alone. Methods: Data from E5194 and ODC were combined. Patients with positive margins or multifocality ...
Researchers performed a retrospective analysis of 3 cohorts of women with prior history breast cancer and rheumatoid arthritis or inflammatory bowel disease to determine the risk of breast cancer recurrence with methotrexate, anti-TNF inhibitors, and thiopurines.
Reducing carbohydrate intake could reduce the risk of breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor, researchers report. Using an unusual approach, this study
&#13;&#13;&#13; &#13; &#13; &#13; &#13; &#13; Managing your&#13; fear of breast cancer recurrence
&#13;&#13;&#13; &#13; &#13; &#13; &#13; &#13; Managing your&#13; fear of breast cancer recurrence
Find out what happens if your breast cancer returns after treatment (recurrence), including information on local and regional recurrence (locally advanced breast cancer).
Although cancer doesnt define my life, it has certainly affected it dramatically. In November 2005, I was diagnosed with rectal cancer and treated throughout 2006. Until recently, there was no evidence of disease after treatment. Now, after unsuccessful attempts at palliative chemotherapy (including Avastin), I have opted for home palliative and hospice care. Quality of life is the goal of my treatment program. My unwanted journey thread will continue to document this significant aspect of my life journey ...
A recent study in the journal JAMA Oncology showed that simple lifestyle changes can reduce lung cancer and colorectal cancer in women by 85% and 60%
Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator. Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11 for a total of 4 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a maximum of 1 year past CR.. Patients are followed at 1 month.. PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for stratum B) will be accrued for this study within 1-2 years. ...
Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator. Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11 for a total of 4 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a maximum of 1 year past CR.. Patients are followed at 1 month.. PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for stratum B) will be accrued for this study within 1-2 years. ...
Sigma-Aldrich offers abstracts and full-text articles by [Lih-Chyang Chen, Li-Jie Wang, Nang-Ming Tsang, David M Ojcius, Chia-Chun Chen, Chun-Nan Ouyang, Chuen Hsueh, Ying Liang, Kai-Ping Chang, Chiu-Chin Chen, Yu-Sun Chang].
We studied the effect of postoperative radiotherapy (RT) after breast sector resection for ductal carcinoma in situ (DCIS). The study protocol stipulated radical surgery but microscopically clear margins were not mandatory. We randomised 1,046 operated women to postoperative RT or control between 1987 and 1999. The primary endpoint was ipsilateral local recurrence. Secondary endpoints were contralateral breast cancer, distant metastasis and death. After a median follow-up of 5.2 years (range 0.1-13.8) there were 44 recurrences in the RT group corresponding to a cumulative incidence of 0.07 (95% confidence interval (CI) 0.05-0.10). In the control group there were 117 recurrences giving a cumulative incidence of 0.22 (95% CI 0.18-0.26) giving an overall hazard ratio of 0.33 (95% CI 0.24-0.47, p , 0.0001). Twenty two percent of the patients had microscopically unknown or involved margins. We found no evidence for different effects of RT on the relative risk of invasive or in situ recurrence. ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
Aims to evaluate prognostic factors for local disease recurrence, distant metastases and cancer survival from anal cancer patients treated with concurrent chemoradiation at the Rosemere Cancer Centre. Zainul Abedin Kapacees short paper presentation at Tripartite 2014. ...
Scientists have identified genetic changes that may predict the likelihood of breast cancer relapse in women taking a common type of hormone therapy.
As part of an ongoing series of answers to common questions received by the Basser Center for BRCA, Executive Director Susan Domchek, MD, discusses typical guidelines for follow up to a potential recurrence of BRCA-related breast cancer.
Information for patients with invasive breast cancer (Stage 1-3a) about a genomic test to help determine whether chemotherapy is right for you.
Results from a new prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect lung cancer recurrence about six months before conventional imaging methods found recurrence.
documentclass{article} % this is the default PlanetMath preamble. as your knowledge % of TeX increases, you will probably want to edit this, but % it should be fine as is for beginners. % almost certainly you want these \usepackage{amssymb} \usepackage{amsmath} \usepackage{amsfonts} % need this for including graphics (\includegraphics) \usepackage{graphicx} % for neatly defining theorems and propositions \usepackage{amsthm} % making logically defined graphics %\usepackage{xypic} % used for TeXing text within eps files %\usepackage{psfrag} % there are many more packages, add them here as you need them % define commands here \begin{document} Let $(X, \mathcal{B}, \mu)$ be a probability space, and let $T_i:X \rightarrow X$ be measure-preserving transformations, for $i$ between $1$ and $q$. Assume that all the transformations $T_i$ commute. If $E\subset X$ is a positive measure set $\mu(E)>0$, then, there exists $n \in \mathbb{N}$ such that $$\mu (E \cap T_1^{-n}(E) \cap \cdots \cap T_q^{-n}(E))>0$$ ...
High-spatial-resolution signal enhancement ratio (SER) imaging mayimprove prediction for patients at high risk for disease recurrence anddeath, according to a study in the July issue of Radiology.
Fifty-one patients were male, 32 female. Median age at diagnosis was 63.9 years (range 34.6-80.6). Most patients had a moderately differentiated adenocarcinoma (66.3%) and TNM disease stage IIB (51.8%). Mean SGLT1 score in primary tumors (n=83) was 4.24 (range 0.5-15.0). Mean Bcl-2 score in primary tumors (n=45) was 0.093 (range 0.0-3.0). Patients with high expression of Bcl-2 had significantly higher mean SGLT1 scores than those with lower Bcl-2 expression: 3.07 versus 5.87 (P=0.025). Mean SGLT1 score in metastases and local recurrent cancer was 2.05 (range 0.5-3.5), which was significantly lower than mean SGLT1 score of their respective primary tumors (3.38, P=0.022). Mean DFS is 12.7 months (median 7.0 months). On uni -and multivariate analysis TNM stage and SGLT1 score showed prognostic value (both P=0.021) for DFS. Mean OS is 20.86 months (median 14.0 months). Both on uni -and multivariate analysis TNM stage retained its prognostic value (P=0.012) and a trend was observed for mean SGLT1 ...
Cancer recurrence - Get the facts and learn to cope with the anger, distress and self-doubt you may feel when your cancer returns.
The PORTEC-1 trial has demonstrated that postoperative external beam radiotherapy for stage 1 endometrial cancer significantly increases local control (from 85 to 96%), but has no impact on survival. Salvage therapy for isolated vaginal recurrence, the main site of recurrence in the control group, was effective with a complete remission rate of 89% and actuarial 5-year survival of 65% in the control group. The use of postoperative RT should therefore be limited to the group of patients at sufficiently high risk of locoregional recurrence (15% or over) to warrant the risk of treatment associated morbidity in order to maximize initial local control and relapse-free survival ...
The goal of lumpectomy surgery for breast cancer is to completely remove the tumor and have clear margins, reducing the rates of local recurrence. The MarginProbe® System is a new device that can detect microscopic tumor cells at or close to the margin of the surgical resection intraoperatively ...
On Tuesday my PET CT came back suggestive of recurrence in the right pelvic sidewall. Because a biopsy at the time of my cancer surgery two years ago told us there were cancer cells there, we knew this day would come. Those cells were sleeping during my remission but appear to have woken up. Getting cancer just as the world goes under with COVID19 is such unimaginable bad luck I can barely comprehend it ...
TT User Setup 7.4.2 introduced support for product margins per market rather than only per flavor. When configuring products that are hosted on more than one gateway flavor per market, you now create only one product margin rather than one for each gateway flavor.. When upgrading from a version prior to 7.4.2, there may be multiple product margins in a market that are already configured for the same product. When the margins are identical for these products, TT User Setup merges them into a single product margin. However, if the product margins are not identical, your TT User Setup administrator must review the conflicts and decide which margin to use. ...
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence rating as an exemplar Goal: Ladies with early-stage, ER + breast most cancers are advocate to obtain genomic profiling checks, such because the 21-gene Recurrence Rating (RS) take a look at, to information remedy selections. We examined test- and treatment-related data mentioned and the associations between RS […]. ...
Once cancer treatment is complete it is time to restore and rejuvenate the body by feeding it with the best foods for optimal nutrition.
Figure 2. Because these patients are not curable, the goal of therapy becomes the improvement in both quality and length of life.
PURPOSE:To investigate the role of quantitative pre-treatment dual-energy computed tomography (DECT) for prediction of loco-regional recurrence (LRR) in patients with larynx/hypopharynx squamous cell cancer (L/H SCC). METHODS:Patients with L/H SCC treated with curative intent loco-regional radiotherapy and that underwent treatment planning with contrast-enhanced DECT of the neck were included. Primary and nodal gross tumor volumes (GTVp and GTVn) were contoured and transferred into a Matlab® workspace. Using a two-material decomposition, GTV iodine concentration (IC) maps were obtained. Quantitative histogram statistics (maximum, mean, standard deviation, kurtosis and skewness) were retrieved from the IC maps. Cox regression analysis was conducted to determine potential predictive factors of LRR. RESULTS:Twenty-five patients, including 20 supraglottic and 5 pyriform sinus tumors were analysed. Stage I, II, III, IVa and IVb constituted 4% (1 patient), 24%, 36%, 28% and 8% of patients, ...
The aim of the present analysis was to evaluate the recurrence pattern in patients with recurrent malignant glioma after re-irradiation in combination with bevacizumab as there is limited data on how to optimally choose dose, fractionation and delineation margins. Thirty-one patients with recurrent malignant glioma treated with re-irradiation and bevacizumab after previous chemoradiotherapy (concurrent temozolomide 75 mg/m2/d according to the EORTC/NCIC trial) and [18 F]FET-PET and/or MRI confirmed recurrence were retrospectively analyzed. Bevacizumab was applied twice during fractionated re-irradiation (10 mg/kg, d1 + d15, median 36 Gy, conventionally fractionated). Recurrence patterns were assessed by means of [18 F]FET-PET and/or MRI. Median follow-up was 34.0 months for all patients [95%-CI, 27.7-40.3] and median post-recurrence survival 10.8 months [95%-CI, 9.2-12.4]. Concerning the recurrence patterns, 61.3% of these were located in-field (19 patients), 22.6% were marginal (7 patients) and 16.1%
TY - JOUR. T1 - A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix. T2 - A Gynecologic Oncology Group study. AU - Fiorica, James V.. AU - Blessing, John A.. AU - Puneky, Louis V.. AU - Secord, Angeles Alvarez. AU - Hoffman, James S.. AU - Yamada, S. Diane. AU - Buekers, Thomas E.. AU - Bell, Jeffrey. AU - Schilder, Jeanne M.. PY - 2009/11/1. Y1 - 2009/11/1. N2 - Purpose: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment. Patients and methods: Women entered on study had or failed one prior chemotherapy regimen in addition to radiosensitizing chemotherapy, performance status less than 3, and adequate hematologic, renal, hepatic, and neurological function. Topotecan was infused at 3.0 mg/m2 on days 1, 8, and 15 every 28 days. Results: Twenty-seven patients were enrolled onto this study with 25 evaluable. ...
The 21-gene recurrence score significantly predicted the risk of recurrence and death in node-positive, estrogen receptor-positive patients treated with adjuvant chemoendocrine therapy, but it did not predict benefit from the addition of paclitaxel to the regimen in a subset of patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial,1 according to Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, Professor of Surgery at Northeastern Ohio Universities College of Medicine and Medical Director of the Comprehensive Breast Program at MD Anderson Cancer Center, Orlando, Florida, and Chairman of the Breast Committee of the NSABP Operations and Biostatistical Center, Pittsburgh, Pennsylvania.. Study Goals. The goal of this substudy was to evaluate the recurrence score as a predictor of the risk of local-regional recurrence in node-positive, estrogen receptor-positive patients treated with adjuvant endocrine therapy and chemotherapy. The secondary goal was to evaluate ...
TY - JOUR. T1 - Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. AU - Dócs, Ottó. AU - Fazakas, Ferenc. AU - Horváth, Nóra Lugosiné. AU - Tóth, L.. AU - András, C.. AU - Horváth, Z.. AU - Méhes, G.. PY - 2014/9/24. Y1 - 2014/9/24. N2 - Colorectal cancer (CRC) is a heterogeneous disease presenting with a wide spectrum of morphological and molecular characteristics sometimes even within the same patient. To understand the mechanisms of oscillations in the KRAS status we evaluated the collective of CRC patients tested using allele-specific PCR and Sanger-sequencing. Mutant KRAS allele was observed in 43.3 % of cases. Repeated analysis of KRAS status in recurrent tumors or metastases was performed in 18/665 cases and a total of 6 cases with different KRAS status was found. In three cases the histological pattern of the tumor was identical. In one patient different histology and molecular status was seen between the primary and the recurrent tumor samples. ...
Obesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models. Doxycycline-inducible primary mammary tumors were generated in intact MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice or orthotopic recipients fed a high-fat diet (HFD; 60% kcal from fat) or a control low-fat diet (LFD; 10% kcal from fat). Following oncogene downregulation and tumor regression, mice were followed for clinical recurrence. Body weight was measured twice weekly and used to segregate HFD mice into obese (i.e., responders) and lean (i.e., nonresponders) study arms, and obesity was correlated with body fat percentage, glucose tolerance (measured using intraperitoneal
The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.
Of the 449 patients who received neoadjuvant chemotherapy, 98 underwent breast-conserving surgery. The average diameter of the tumors was 5.3 cm, and 87.2% reached a size of up to 3 cm. Moreover, 86.7% were classified as clinical stage III, 74.5% had T3-T4 tumors, 80.5% had N1-N2 axilla, and 89.8% had invasive ductal carcinoma. A pathologic complete response was observed in 27.6% of the tumors, and 100.0% of samples had free margins. The 5-year actuarial overall survival rate was 81.2%, and the mean follow-up was 72.8 months. The rates of ipsilateral breast tumor recurrence and locoregional recurrence were 11.2% and 15.3%, respectively. Multifocal morphology response was the only factor related to ipsilateral breast tumor recurrence disease-free survival ...
The prognostic role of positive circumferential resection margins after curative intent surgery for locally advanced esophageal adenocarcinoma
The management of rectal cancer has changed in many countries over the last two decades and resulted in improved survival for the majority of rectal cancer patients. In this thesis some surgical strategies and histopathological aspects to improve and clarify the management of rectal cancer patients are investigated.. Even in the era of TME surgery and radiotherapy, a higher local recurrence rate and shorter survival for rectal cancer patients operated with abdominoperineal resection is reported. In the first paper we describe a new strategy with partial anterior en bloc resection of either the prostate or the vagina, resulting in very low local recurrence rates and excellent long-term survival. Histopathological examination of the specimen lays the foundation for decision making on oncological therapy. A positive circumferential resection margin (CRM) has, in previous papers, been related to a high risk of local recurrence. In the second paper we show that a CRM ≤ 1 mm was not correlated with ...
BACKGROUND: In breast cancer patients (≥70 years), tumour resection plus tamoxifen (T + T) has a higher loco-regional relapse (LR) rate than mastectomy. This study examines factors influencing local recurrence in these cases. METHODS: Clinical records of 71 patients aged ≥70 years, randomised to the T + T arm of 2 randomised trials were reviewed. Cox Proportional Hazards model was used to determine the most significant variables. RESULTS: After 15-years follow-up, LR relapse occurred in 29/71, of whom 5 had synchronous metastatic disease. Most tumours recurred in the index quadrant. Subsequently 21/24 patients with loco-regional recurrence only had salvage mastectomy. Three variables significantly predicted LR: lympho-vascular invasion (LVI) (HR [95% CI]: 11.18 [4.47, 27.95], p | 0.01), ER negative status (HR [95% CI]: 0.27 [0.10, 0.72] p = 0.01), and tumour necrosis (HR [95% CI]: 2.65 [1.10, 6.37], p = 0.03). Final margin status was not associated with LR. CONCLUSIONS: Tumour resection + Tamoxifen
Statins and risk of breast cancer recurrence Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had
Read Erratum to: Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review, World Journal of Urology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Six modern, prospective, randomized trials have demonstrated that breast-conserving therapy (lumpectomy followed by radiation) offers survival rates equivalent to mastectomy (Table 61-1)1-7; however, when negative margins are not achieved or when radiation therapy is not pursued, breast conservation is associated with higher rates of local recurrence (Tables 61-1 and 61-2).1,2,8-14 Until recently, the impact of local recurrence on survival remained unclear. In 2005, the Early Breast Cancer Trialists Collaborative Group (EBCTCG) published the results of a large meta-analysis combining all individual patient data for 42,080 women who collectively took part in 78 treatment comparisons (more vs less surgery, more surgery vs radiotherapy, radiotherapy vs none) to determine the impact of local recurrence on survival. Specifically, among 10 breast-conservation trials included in the EBCTCG analysis (7311 women), postoperative radiation treatment (XRT) was associated with a statistically significant ...
The present invention relates to a scoring system for the prediction of cancer recurrence. More particularly, the present invention concerns with the selection of genes and/or proteins, and generation of formulae with the selected genes and/or proteins for the prediction of cancer recurrence by measuring the expression of genes and/or proteins of human tumor tissues, and comparing their patterns with those of the gene and/or protein expression of human primary tumors from patients who have cancer recurrence and those who do not have cancer recurrence. The present invention also relates to a kit for performing the method of the present invention comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction (hereinafter referred to
With the increasing incidence of ESCC in Asia, it has been reported that the recurrence rate of patients with ESCC following surgery ranges from 36.1% to 64.2%.[6, 20, 21]. Overall survival rates at 2 and 5 years are 22% and 11%, respectively, with a median survival time of only 7 months[16, 17]. Locoregional recurrence after curative esophagectomy in patients with esophageal cancer remains a challenge to clinical oncologists, regardless of the pathological type. The National Comprehensive Cancer Network (NCCN) guidelines indicate that a subgroup of patients with postoperative locoregional recurrence may be able to tolerate concurrent radiochemotherapy[9, 16, 26]. The limited survival benefit may arise from the limited competence of the routine radiation technique. With the disadvantage of localization using 2-dimensional radiation fields, the radiation doses for the targeted tumor in patients with locoregional recurrent ESCC could not satisfy the demands of the prescribed doses. Curative ...
As mentioned, one of the most important partners in allowing or preventing metastatic cell survival and growth is immune cancer surveillance [20]. If immune surveillance and its proper balance are key to prevent or fight against an effective metastatic process, it is likely that disruption of the immune surveillance system plays a key role in the recognition of HCC recurrence. Immune surveillance is the result of several factors that are the consequence of the relationship between the personal inflammatory/immune phenotype and the modification of the inflammation process that is in place during viral infection and its modification by effective therapy. Thus, inflammatory status with heterogeneous activation of stromal cells and lymphocyte recruitment is sure responsible for the delay, or even complete abrogation, of the growth of clones of cells that may have nested away from the primary tumor. In the setting of DAA-based antiviral therapy, there is an extremely fast inhibition of HCV ...
Local recurrence is a major cause of morbidity and mortality, usually implies a worse prognosis. It may occur as a result from two potential etiopathogeneses. First, metastases through endothelial-lined channels occur to both lymphatic and hematogenous routes [18], which are controlled by neoadjuvant therapy and optimal TME. Indeed, TME reduced the high local recurrence rates from 30-40% to 5-10% [19] and even greater when associated with chemoradiotherapy (CRT) [20]. The second is by implantation of viable exfoliated malignant cells from a rectal adenocarcinoma on preexisting benign perineal lesions [21-24]; it was estimated that 70% of the specimens were found to have viable exfoliated colorectal cancer cells with median cell number ranging from 0.55 × 105 to 0.78 × 10 [6].. Since the first case of cell implantation into the anal fistula in 1954 by Guiss [4], several case reports and small case series reported the colorectal cancer recurrence on preexisting benign perineal lesions such as ...
and LinkedIn.. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the Oncotype DX Breast Recurrence Score test to physicians, patients and payors; the results of the TAILORx study including its implications on clinical treatment decisions; the ability of the Oncotype DX Breast Recurrence Score test to improve patient outcomes; and the ability of the company to expand commercial access and increase utilization of its Oncotype DX Breast Recurrence Score test. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical studies; the applicability of clinical study results to actual outcomes; the ability of the test results to change treatment ...
Despite improvements in adjuvant therapy, late systemic recurrences remain a lethal consequence of both early- and late-stage breast cancer. A delayed recurrence is thought to arise from a state of tumor dormancy, but the mechanisms that govern tumor dormancy remain poorly understood. To address the features of breast tumors associated with late recurrence, but not confounded by variations in systemic treatment, we compiled breast tumor gene expression data from 4,767 patients and established a discovery cohort consisting of 743 lymph node-negative patients who did not receive systemic neoadjuvant or adjuvant therapy. We interrogated the gene expression profiles of the 743 tumors and identified gene expression patterns that were associated with early and late disease recurrence among these patients. We applied this classification to a subset of 46 patients for whom expression data from microdissected tumor epithelium and stroma was available, and identified a distinct gene signature in the stroma and
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial t
True or False. A positive margin which is defined as ink on ductal carcinoma in situ (DCIS) is associated with an increase in ipsilateral breast tumor recurrence (IBTR), which is nullified by the use of whole-breast radiation therapy (WBRT). ...
See also bug #70693 Activesyncd is losing the nth attribute for monthly repeating BYDAY events. The following EAS data: ,Recurrence xmlns=Calendar:, ,Recurrence_Type,3,/Recurrence_Type, ,Recurrence_Interval,1,/Recurrence_Interval, ,Recurrence_WeekOfMonth,1,/Recurrence_WeekOfMonth, ,Recurrence_DayOfWeek,16,/Recurrence_DayOfWeek, ,/Recurrence, is turned into the following RRULE: RRULE:FREQ=MONTHLY;BYDAY=TH which should be: RRULE:FREQ=MONTHLY;BYDAY=1TH This is obviously related to bug #70693. Until I investigate further, I dont know if this is caused by the same underlying problem as that bug, is a deliberate attempt to avoid triggering that bug or is a separate bug. Even if this is separate, bug #70693 may still prevent the corrected event from being synchronised. As events with recurrence like first Monday of the month are very common, it would be nice to fix this ...
Treatment of recurrent breast cancer depends mainly on where the cancer recurs and past treatment. Learn about treatment of local or metastatic recurrence.
Treatment of recurrent breast cancer depends mainly on where the cancer recurs and past treatment. Learn about treatment of local or metastatic recurrence.
Approximately 10% to 15% of patients with stage I/II invasive breast cancer will develop a clinically isolated local recurrence. The standard management of an ipsilateral breast tumor recurrence following breast- ...
Eliminating pro-inflammatory cells after treatment relieves symptoms in mice.. January 17, 2017/Novato, California: Standard chemotherapy is a blunt force instrument against cancer - and its a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body. Researchers at the Buck Institute and elsewhere now show that chemotherapy triggers a pro-inflammatory stress response termed cellular senescence, promoting the adverse effects of chemotherapy as well as cancer relapse and metastasis. Eliminating the senescent cells in mice prevented the side effects and relapse. The research is published in Cancer Discovery.. While chemotherapy does save lives, it often comes with a very high price, said Judith Campisi, PhD, Buck faculty and senior scientist on the study. Our work in mice studied the effects of chemotherapy on cancer relapse and other serious side effects. It provides a ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
TY - JOUR. T1 - Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer. T2 - A case-control study. AU - Haffty, Bruce G.. AU - Brown, Felix. AU - Carter, Darryl. AU - Flynn, Stuart. PY - 1996/7/1. Y1 - 1996/7/1. N2 - Purpose: The purpose of this study is to determine the prognostic significance of overexpression of the HER-2 neu oncoprotein with respect to local relapse following conservative surgery and radiation therapy (CS+RT). Methods and Materials: Twenty consecutive patients who sustained a local recurrence as the first and only site of failure following CS+RT comprised the case population base for this study. Only patients who received no adjuvant systemic chemotherapy or tamoxifen were selected for analysis. Following the identification of 20 consecutive local-relapse patients, the patient database was searched for 20 matching control patients who did not sustain a local relapse. Each control patient was ...
Optimizing the odds of avoiding cancer recurrence: Go jogging in your Speedo or bikini!. I have been looking around, mostly on pubmed ( https://www.ncbi.nlm.nih.gov/pubmed/ ), for non-chemotherapy strategies to reduce cancer recurrence and mortality. To avoid an overlong post, I will summarize very briefly the information I have found, with hopefully a link to one supporting study. If the topic interests you, I encourage you to go to pubmed and read more. Of course, all of this information is from my perspective only and you should use it as a springboard for discussion with your doctor or your own research.. Vitamin D: One of the most surprising results of my research was the impact of vitamin D on colorectal cancer recurrence and mortality. One article reports, Freedman et al demonstrated in one of the largest prospective studies including 16,818 participants that CRC mortality was inversely related to serum 25(OH)D level. Individuals with serum levels of 50-80 ng/mL and , 80 ng/mL had a ...
While we do not talk about recurrence much in my family, everyone knows way too much about it because we all remember my mothers experience. She was diagnosed at an early stage. Low grade. Her cancer still metastasized.. Broadly speaking, the greatest risk of recurrence is during the first two years following diagnosis. Certain more aggressive breast cancers are more likely to metastasize early on, before the five year benchmark. Others, like my mothers and mine (ER+,PR+), are less likely to metastasize early on, but can and sometimes do many years later. A reader (thank you) shared this piece, Understanding the Risk of Late Recurrence of Breast Cancer.. The bottom line is, theres no guarantee. The five-year benchmark suggesting youre cured is a myth that has been perpetuated for years partly due to Pink Ribbon Fantasy Land hype.. Many women (and men) do struggle with recurrence worries.. Perhaps adding to this worry (for me anyway and perhaps for you, too) is the fact that generally ...
Eighty-five patients met the inclusion criteria, and 27% of them had an atypical histology. Typical EVNs had a better prognosis than atypical EVNs after primary treatment, with a 5-year recurrence rate of 36% compared with 68% (p , 0.001), and a 5-year mortality rate of 4% compared with 44%, respectively (p , 0.001). Age younger 50 years was associated with a better prognosis than age equal to or greater than 50 years, with a 5-year recurrence rate of 33% and 74%, respectively (p , 0.001), and a 5-year mortality rate of 4% and 52%, respectively (p , 0.001). Multivariate analysis demonstrated that atypical EVNs carried significantly increased risk for recurrence (hazard ratio [HR] 4.91, p , 0.001) and death (HR 22.91, p , 0.01). Gross-total resection was superior to subtotal resection (STR) alone in tumor control rates for typical EVNs (95% and 68%, p , 0.05), and there was a trend for adjuvant external-beam radiotherapy to benefit STR. There was suggestion of similar trends in patients with ...
Immunotherapy (tumor vaccine) is recommended for dogs with malignant melanoma because of the high risk of metastasis to the lymph nodes and lungs. Chemotherapy is recommended for dogs with oral osteosarcoma. Chemotherapy should also be considered for other oral tumors and the palliative management of cats with SCC.. PROGNOSIS. Dogs. Malignant Melanoma. Malignant melenoma is the most common oral tumor in dogs and also has the highest metastatic potential, particularly to the regional lymph nodes and lungs. Based on a combination of early papers, the local recurrence rate following mandibulectomy was 22% with a median survival time of 9-11 months and a 1-year survival rate of 21%. Similarly, the local recurrence rate following maxillectomy is as high as 48% with a median survival time of 5-10 months and a 1-year survival rate of 27%. However, in two large 2014 studies, the overall local recurrence rate was 16%-17%. Clinical stage has prognostic significance with median survival times of 20 months ...
There has been scanty data regarding the clinical significance of tumor conspicuity in pancreatic cancer. In this study, we attempted to investigate the prognostic significance of pancreatic tumor conspicuity and determine prognostic factors for postoperative recurrence in patients with surgically resected pancreatic cancer. Between January 2011 and September 2019, 62 patients who underwent preoperative computed tomography (CT) for pancreatic cancer were retrospectively included. Two reviewers evaluated various clinical, imaging, and pathologic variables and reviewed all available medical records to determine patient outcomes after surgery. Tumor conspicuity was defined as the attenuation ratio between normal parenchyma and tumor lesions on dynamic-enhanced CT images and represented the conspicuity score. Recurrence-free survival and overall survival were investigated using Cox regression analysis. Patient mean age was 65.9 (±11.6) years, and 56.5% were male. The median follow-up period was 11 months
Recurrent Breast cancer can return after successful treatment. The initial treatment involves eliminating all cancer cells, but it is possible for a few to
Although the initial cancer treatment is aimed at eliminating all cancer cells, a few of them may still stay in the body, which likely cause breast cancer recurrence. Breast cancer can recur at any time but mostly occur in the first three to five year
The main objective of the current investigation was to study the efficacy of EPA as an inhibitor of recurrent colorectal cancer growth and to determine whether EPA in combination with FuOx would be more effective than either agent/regimen alone.. The preventive and therapeutic efficacy of a combination of EPA and DHA or each PUFA alone has been demonstrated in multiple preclinical studies using a variety of rodent models of early-stage colorectal cancer (37). These studies have consistently demonstrated reduction in colorectal cancer incidence (reviewed in ref. 37). Our data demonstrate for the first time that EPA acts synergistically with FuOx to markedly inhibit the growth of chemoresistant colon cancer cells that form bulk of the recurrent tumor. Although the underlying cause for tumor recurrence is not fully understood, one of the reasons is thought to be the presence of CSCs/CSLCs that are resistant to conventional chemotherapy and retain limitless potential to regenerate (1-3, 38). The ...
Process monitoring is an important research problem in numerous areas. This paper proposes a novel process monitoring scheme by integrating the recurrence plot (RP) method and the control chart technique. Recently, the RP method has emerged as an effective tool to analyze waveform signals. However, unlike the existing RP methods that employ recurrence quantiﬁcation analysis (RQA) to quantify the recurrence plot by a few summary statistics; we propose new concepts of template recurrence plots and continuous-scale recurrence plots to characterize the waveform signals. A new feature extraction method is developed based on continuous-scale recurrence plot. Then, a monitoring statistic based on the top- approach is constructed from the continuous-scale recurrence plot. Finally, a bootstrap control chart is built to detect the signal changes based on the constructed monitoring statistics. The comprehensive simulation studies show that the proposed
For treatment, most women with newly diagnosed ovarian cancer undergo surgery to remove as much of the visible tumor as possible and determine a specific diagnosis. Survival time is markedly better for women who have complete tumor removal, yet great variability exists in the extent of tumor removal. For women in whom an optimal removal is not feasible, or who are unable to undergo surgery, neoadjuvant chemotherapy can reduce tumor size and facilitate subsequent surgical resection. While the majority of women respond well to initial treatments, most will experience a recurrence of ovarian cancer, and virtually all recurrent ovarian cancers ultimately become resistant to current drug therapies. The committee said there is a need for better tools to predict near- and long-term response to treatments for both newly diagnosed and recurrent cancers.. While clinicians should have better ways to select the most appropriate treatment for individual patients, they also require more treatment options, and ...
Weill Cornell Medicine is one of only a handful of locations in the United States enrolling patients in this innovative trial for GBM
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the genetic mutation screening multicenter study that he was the lead author for and presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Portrait of Mark Ptashne (born 1940), US molecular biologist. Ptashne was the first scientist to demonstrate specific binding between protein and DNA. Much of his research has focused on molecular mechanisms in the lifecycle of the virus bacteriophage lambda. He holds the Ludwig Chair of Molecular Biology at Memorial Sloan-Kettering Cancer Center in New York, where he works on gene regulation mechanisms in yeast. - Stock Image C021/9054
CVSROOT: /cvs/purrs Module name: purrs Changes by: zolo at cs.unipr.it 2003-11-14 12:45:47 Modified files: demos : purrs_rrs_cgi.cc src : Recurrence.cc Recurrence.defs.hh Recurrence.inlines.hh rr_classifier.cc tests : rrs_driver.cc Log message: Removed the status HAS_HUGE_DECREMENT from Solver_Status. Now the status HAS_HUGE_DECREMENT of Classifier_Status is mapped in the status TOO_COMPLEX of Solver_Status. Added and fixed several comments. Patches: http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/demos/purrs_rrs_cgi.cc.diff?cvsroot=purrs&r1=1.24&r2=1.25 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.cc.diff?cvsroot=purrs&r1=1.121&r2=1.122 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.defs.hh.diff?cvsroot=purrs&r1=1.126&r2=1.127 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.inlines.hh.diff?cvsroot=purrs&r1=1.88&r2=1.89 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/rr_classifier.cc.diff?cvsroot=purrs&r1=1.75&r2=1.76 ...